From: The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study
Clinical phenotype | Variables | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
 |  | OR (95% CI) | P value | OR (95% CI) | P value |
OMG (n = 107) | Baseline MG-ADL | 1.843 (1.335, 2.543) |  < 0.001* | 2.318 (1.486, 3.616) |  < 0.001* |
Age at the onset | 0.963 (0.944, 0.983) |  < 0.001* | 0.948 (0.920, 0.977) |  < 0.001* | |
Onset in March | 12.800 (1.208, 135.579) | 0.034* | 7.282 (0.524, 101.183) | 0.139 | |
Vaccination | 0.198 (0.042, 0.942) | 0.042* | 0.399 (0.049, 3.240) | 0.399 | |
GMG (n = 87) | Affect Limb muscles | 0.351 (0.131, 0.942) | 0.038* | 0.705 (0.232, 2.143) | 0.537 |
Prednisolone | 3.867 (1.055, 14.178) | 0.041* | 2.012 (0.478, 8.462) | 0.340 | |
Baseline MG-ADL | 1.495 (1.154, 1.935) | 0.002* | 1.374 (1.040, 1.814) | 0.025* |